Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9–11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major pro...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2009
Fag:	Clinical Study
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2634671/ https://ncbi.nlm.nih.gov/pubmed/19066607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604818
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

Lignende værker